Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OPC 224333

Next Previous
X
Search
Drug Profile

OPC 224333

Alternative Names: OPC-224333

Latest Information Update: 26 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical Development & Commercialization
  • Class Antiepileptic drugs
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 26 Jul 2024 Phase-I clinical trials in Epilepsy in USA (PO), prior to July 2024 (Otsuka Pharmaceutical pipeline, July 2024)
  • 25 Mar 2022 OPC 224333 is available for licensing as of 25 Mar 2022. https://www.otsuka-us.com/collaborations
  • 25 Mar 2022 Otsuka Pharmaceutical plans a phase I trial in Epilepsy (In volunteers) in Australia (PO, Tablets) in March 2022 (ACTRN12622000460707)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top